

HEALTHCARE MONTHLY

SEPTEMBER 2023

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

(EXACTCARE

NAUTIC

🦺 TabulaRasa

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics **Medical Devices**



ACQUIROR Life Sciences / Diagnostics Danaher Corp (NYSE:DHR) has reached a definitive agreement to acquire Abcam plc (NASD:ABCM) Danaher is a US-based manufacturer and marketer of medical and laboratory tools including microscopes, blood analyzers and cell testing devices, along with dental and electrical calibration equipment · Abcam is a UK-based developer and provider of antibodies to life science research and clinical communities Total Consideration: \$5.7 billion Per share price represents a premium of 10.9% Novo Nordisk, A/S (CPH:NOVO-B) has reached a definitive agreement to acquire Inversago Pharma, Inc. BioTech / Pharma · Novo Nordisk is a Denmark-based manufacturer and marketer of medicines and other treatments for diabetes, hemophilia, obesity and other inversago 🗡 Inversago Pharma is a Canada-based developer of CB1 receptor-based therapies for potential treatment of obesity, diabetes and complications associated with metabolic disorders Total Consideration: \$1.1 billion · PureHealth, LLC has reached a definitive agreement to acquire Circle Health, Ltd. from Centene Corp (NYSE:CNC) · PureHealth is a UAE-based integrated healthcare network that includes hospitals, clinics, diagnostics, insurance, pharmacies and health tech circlehealth Circle Health operates 53 hospitals across the UK, providing a wide range of surgery and treatments to privately-insured, self-pay and NHS Ρυκσησαιτή Centene Corp provides managed care and specialty services to under-insured and uninsured families, commercial organizations and military families in the US **lealthcare Services** Total Consideration: \$1.2 billion ExactCare Pharmacy, LLC, a portfolio company of Nautic Partners, has reached a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NASD:TRHC) ExactCare is a national medication management and home care health provider that specializes in supporting patients with complex medical

administrative burdens and reduce hospitalizations

· Per share price represents a premium of 34.1%


- Total Consideration: \$570 million

· Tabula Rasa Healthcare provides technology solutions for health plan providers and hospital systems to optimize medication regimens, reduce




HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
Zynerba Pharmaceuticals, Inc. (NASD:ZYNE)	Harmony Biosciences Holdings, Inc. (NASD:HRMY)	Zynerba develops and commercializes synthetic cannabinoid therapeutics for transdermal delivery Total Consideration: \$60m in cash; \$140m in earnout Per share price represents a premium of 226%
Decibel Therapeutics, Inc. (NASD:DBTX)	Regeneron Pharmaceuticals, Inc. (NASD:REGN)	Decibel develops therapeutics targeted at restoring hearing loss and balance through a platform of single-cell genomics and precision gene therapy Total Consideration: \$109m in cash; \$104m in earnout Per share price represents a premium of ~169%
Serina Therapeutics, Inc.	AgeX Therapeutics, Inc. (NYSE: AGE)	Serina develops small molecule therapeutics targeting the central nervous system; its lead drug candidate targets advanced Parkinson's
Target	Acquiror	Life Sci / Diagnostics Transactions
PhenomeX, Inc. (NASD:CELL)	Bruker Corp (NASD:BRKR)	PhenomeX develops and provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages Total Consideration: \$117m in cash Per share price represents a premium of ~150%
Chiron, A.S.	Antylia Scientific (GTCR, LLC)	Chiron, based in Norway, manufactures advanced chemical reference materials for toxicological, environmental, food safety and petroleum analysis
Sunbird Bio, Inc.	Glympse Bio, Inc. (Temasek Holdings Pte, Ltd.)	Sunbird Bio develops protein-based diagnostic tests to enable more accurate detection, measurement and treatment of Alzheimer's, neurological diseases and early-stage cancer

Selected TM Capital Healthcare Experience









AlterG, Inc.

ReWalk Robotics, Ltd.
(NASD:RWLK)

AlterG develops mobility enhancing products used for athletic training and physical & neurological rehabilitation
Total Consideration: \$19m in cash

VisionAir Solutions,

LLC (The Cleveland Clinic Foundation)

Theken Companies, LLC

VisionAir manufactures silicone pulmonary stents customized to patients' airway anatomy using its 3D-design software platform

Infection Control Technology, LLC MicroCare, LLC (Heartwood Partners) Infection Control Technology manufactures infection control chemistries for the dental market, with various applications including instrument reprocessing, evacuation system cleaning and hard surface disinfection

TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Principal jdean@tmcapital.com 404.995.6234



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232

